Journal of
Translational Medicine

CORRECTION

CrossMark

Correction to: Open-label pilot for treatment targeting gut dysbiosis in myalgic encephalomyelitis/chronic fatigue syndrome: neuropsychological symptoms and sex comparisons

Amy Wallis[1*] , Michelle Ball[1], Henry Butt[2], Donald P. Lewis[3], Sandra McKechnie[4], Phillip Paull[2], Amber Jaa-Kwee[4] and Dorothy Bruck[1]

Correction to: J Transl Med (2018) 16:24
https://doi.org/10.1186/s12967-018-1392-z

The original version of this article [1], published on 6 February 2018, contains a mistake in the 'Conclusions' section. The corrected version of the affected sentence is given below and the corrected part is marked in bold.

- It is unclear whether the reduction in *Streptococcus* is particularly beneficial in some ME/CFS patients or whether other concurrent microbial shifts are equally or more valuable (**i.e., increased *Bacteroides* and/or reduced *Clostridium***).

Author details
[1] Psychology Department, College of Health and Biomedicine, Victoria University, Melbourne, Australia. [2] Bioscreen (Aust) Pty Ltd., Melbourne, Australia. [3] CFS Discovery Clinic, Donvale, Melbourne, Australia. [4] College of Engineering and Science, Victoria University, Melbourne, Australia.

The original article can be found online at https://doi.org/10.1186/s12967-018-1392-z.

Reference
1. Wallis A, Ball M, Butt H, Lewis DP, McKechnie S, Paull P, Jaa-Kwee A, Bruck D. Open-label pilot for treatment targeting gut dysbiosis in myalgic encephalomyelitis/chronic fatigue syndrome: neuropsychological symptoms and sex comparisons. J Transl Med. 2018;16:24. https://doi.org/10.1186/s12967-018-1392-z.

*Correspondence: Amy.Wallis@vu.edu.au
[1] Psychology Department, College of Health and Biomedicine, Victoria University, Melbourne, Australia
Full list of author information is available at the end of the article

BioMed Central